ThinkCyte Gains Traction as Kyoto University and Scripps Highlight VisionSort Platform

ThinkCyte featured prominently this week as its AI-driven VisionSort cell-sorting platform gained traction at leading research institutions. The company reported that Kyoto University’s Center for iPS Cell Research and Application (CiRA), a globally recognized iPSC hub, has adopted VisionSort for regenerative medicine and cell therapy workflows.

CiRA plans to leverage VisionSort’s high-speed imaging and AI-enabled sorting to support advanced stem cell and iPSC research, potentially accelerating translational programs. While financial terms were not disclosed, placement at such a prestigious center provides important validation of the technology and could serve as a reference site for other academic and biopharma customers.

ThinkCyte also highlighted an educational collaboration with Scripps Research, promoting a live webinar showcasing its Ghost Cytometry technology and VisionSort platform. The event, led by the company’s Head of Research, is designed to demonstrate label-free, morphology-based cell analysis that can uncover novel phenotypes while preserving cell viability.

The Scripps-focused content targets researchers in immunology, translational science, and drug discovery, emphasizing workflow integration into existing lab infrastructures. This outreach underscores ThinkCyte’s strategy to build scientific adoption, enhance credibility in flow cytometry and AI-in-biology, and position its label-free capabilities as a differentiated solution in competitive cell analysis markets.

Collectively, the CiRA deployment and Scripps webinar point to a week of growing visibility and validation for ThinkCyte’s VisionSort platform. These developments may improve the company’s long-term commercialization prospects by strengthening its brand among top-tier research institutions and laying groundwork for broader adoption in drug discovery and regenerative medicine applications.